Blue Jet Healthcare (BLUEJET) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue was Rs. 3,547.58 mn, up 117.8% YoY, driven mainly by pharma intermediates and APIs.

• EBITDA was Rs. 1,210 mn and PAT Rs. 911.70 mn; both rose strongly YoY and declined QoQ.

• The portfolio included 511 commercialized products in FY25 across contrast media, high-intensity sweeteners, and pharma intermediates and APIs.

Financial highlights

• Revenue from operations was Rs. 3,547.58 mn, up 117.8% YoY; total income was Rs. 3,630.12 mn.

• EBITDA was Rs. 1,210 mn, down 13.6% QoQ and up 173.3% YoY; margin was 34.1%.

• PAT was Rs. 911.70 mn, down 17.2% QoQ and up 141.3% YoY; margin was 25.7%.

• Gross margin was 48.4%, versus 54.7% in Q4 FY25; inventory drawdown and product mix reduced overhead absorption.

• Profit before tax was Rs. 1,228.60 mn and tax expense Rs. 316.90 mn; EPS was Rs. 5.26.

Outlook and guidance

• FY26 confidence was supported by customer demand, available capacity, and an expanding product pipeline; production is order-led, with Q2/Q3 planned to return to original levels.

• Management expects gross margin near 53% with the current portfolio mix and cited Q4 and Q1 combined gross margin of 53%; no forward gross-margin guidance was given.

• Contrast media growth is expected from iodinated products and gadolinium-based supplies; management aspires to regain FY23 levels in FY25 or FY26, with full-year iodinated-molecule impact in FY27.

• Strategic priorities include capacity expansion, R&D investment, operating efficiency, supply-chain risk mitigation, and higher-value contrast media and adjacent pharma intermediate/API opportunities.